Insulin Aspart Biosimilar
Diabetes Mellitus
Key Facts
About USV Biologics Division
Indian pharma company delivering generics and biosimilars with a strong API manufacturing base.
View full company profileAbout Meitheal Pharmaceuticals
Meitheal Pharmaceuticals is a private, commercial-stage biopharma company focused on generic injectables and biosimilars. Leveraging a partnership-driven model, it has built a diverse pipeline and product portfolio targeting therapeutic areas such as anti-infectives, oncology, diabetes, fertility, and immunology. The company emphasizes robust manufacturing, steady supply, and rapid market response to address unmet needs and improve drug affordability. Its recent expansion into biosimilars with the acquisition of YUSIMRY® and launch of products like liraglutide injection signals a strategic growth phase.
View full company profileAbout Biocon
Biocon's mission is to deliver affordable, high-quality biopharmaceuticals to a global patient population. The company has achieved global leadership in biosimilars, with multiple commercialized products in oncology, immunology, and diabetes, and has built a fully integrated platform from R&D to manufacturing. Its strategy is anchored in leveraging its deep bioprocessing expertise to expand its biosimilar portfolio, advance a pipeline of novel biologics, and grow its contract research and manufacturing services.
View full company profileTherapeutic Areas
Other Diabetes Mellitus Drugs
| Drug | Company | Phase |
|---|---|---|
| Sirolimus-Coated Balloon (SCB) - DEDICATE Registry | Concept Medical | Registry |
| Gensulin (Human Insulin) | Bioton | Approved |
| Insulin Biosimilars Portfolio | GEROPHARM | Approved/Commercial |
| Biosimilar Insulin Glargine | Wockhardt | Launched |
| Biosimilar Insulin Aspart | Wockhardt | Launched |
| Human Insulin | EVA Pharma | Approved |
| Insulin Glargine | Biomm | Approved |
| Insulin Analog Formulations | RPG Life Sciences | ANDA Filed/Development |